Publications

2019

Patel SS, Pinkus GS, Ritterhouse LL, Segal JP, Dal Cin P, Restrepo T, et al. High NPM1 mutant allele burden at diagnosis correlates with minimal residual disease at first remission in de novo acute myeloid leukemia. Am J Hematol. 2019;94(8):921-928.
Nellis ME, Goel R, Karam O, Cushing MM, Davis PJ, Steiner ME, et al. International Study of the Epidemiology of Platelet Transfusions in Critically Ill Children With an Underlying Oncologic Diagnosis. Pediatr Crit Care Med. 2019;20(7):e342-e351.
Baum JE, Soong L, Scognamiglio T, Margolskee EM, Hoda RS, Rao R. Cytological diagnosis of papillary thyroid carcinoma with tall cells on ThinPrep liquid-based cytology. Diagn Cytopathol. 2019;47(6):541-546.
Randall EC, Zadra G, Chetta P, Lopez BG, Syamala S, Basu SS, et al. Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging. Mol Cancer Res. 2019;17(5):1155-1165.
Sun L, Thorson T, Zhu R, Huo J, Tong J, Rodgers WH, et al. A case report of parotid mammary analogue secretory carcinoma and reviews. Int J Surg Case Rep. 2019;55:88-91.
Westblade LF, Satlin MJ, Albakry S, Botticelli B, Robertson A, Alston T, et al. Gastrointestinal pathogen colonization and the microbiome in asymptomatic kidney transplant recipients. Transpl Infect Dis. 2019;21(6):e13167.
Frost EL, Mockus TE, Ren HM, Toprak M, Lauver MD, Netherby-Winslow CS, et al. PD-1 Dynamically Regulates Inflammation and Development of Brain-Resident Memory CD8 T Cells During Persistent Viral Encephalitis. Front Immunol. 2019;10:783.
Labbé DP, Zadra G, Yang M, Reyes JM, Lin CY, Cacciatore S, et al. High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. Nat Commun. 2019;10(1):4358.
Canver MC, Tekle T, Compton ST, Callan K, Burd EM, Zimmer BL, et al. Performance of Five Commercial Identification Platforms for Identification of Staphylococcus delphini. J Clin Microbiol. 2019;57(11).
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, et al. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019;25(1):43-51.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700